Page 21 - 2019_02-Haematologica-web

Editorials
8. Kneppers E, van der Holt B, Kersten MJ, et al. Lenalidomide mainte- nance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood. 2011;118(9):2413-2419.
9. Alsina M, Becker PS, Zhong X, et al. Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell trans- plantation. Biol Blood Marrow Transplant. 2014;20(8):1183-1189.
10. Kroger N, Zabelina T, Klyuchnikov E, et al. Toxicity-reduced, myeloab- lative allograft followed by lenalidomide maintenance as salvage ther- apy for refractory/relapsed myeloma patients. Bone Marrow Transplant. 2013;48(3):403-407.
11. Engelhardt M, Domm AS, Dold SM, et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017;102(5):910-921.
12. Bjorkstrand B, Iacobelli S, Hegenbart U, et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell trans- plantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol. 2011;29(22):3016-3022.
13. Bruno B, Rotta M, Patriarca F, et al. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood. 2009;113(14):3375-3382.
14. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356(11):1110-1120.
15. Gahrton G, Iacobelli S, Bjorkstrand B, et al. Autologous/reduced-inten- sity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood. 2013;121(25):5055-5063.
16. Garban F, Attal M, Michallet M, et al. Prospective comparison of autol- ogous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107(9):3474-3480.
17. Giaccone L, Storer B, Patriarca F, et al. Long-term follow-up of a com- parison of nonmyeloablative allografting with autografting for newly
diagnosed myeloma. Blood. 2011;117(24):6721-6727.
18. Krishnan A, Pasquini MC, Logan B, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
Lancet Oncol. 2011;12(13):1195-1203.
19. Moreau P, Garban F, Attal M, et al. Long-term follow-up results of
IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotrans- plantation with autologous transplantation in high-risk de novo multi- ple myeloma. Blood. 2008;112(9):3914-3915.
20. Rosinol L, Perez-Simon JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood. 2008;112(9):3591-3593.
21. Rotta M, Storer BE, Sahebi F, et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood. 2009;113(14):3383-3391.
22. Armeson KE, Hill EG, Costa LJ. Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront manage- ment of multiple myeloma: meta-analysis of trials with biological assignment. Bone Marrow Transplant. 2013;48(4):562-567.
23. Sobh M, Michallet M, Gahrton G, et al. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia. 2016;30(10):2047-2054.
24. Scott EC, Hari P, Kumar S, et al. Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. Biol Blood Marrow Transplant. 2018;24(12):2443-2449.
25. Kroger N, Badbaran A, Zabelina T, et al. Impact of high-risk cytogenet- ics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant. 2013;19(3):398-404.
haematologica | 2019; 104(2)
225